

Human TRAILR4/TNFRSF10D Alexa Fluor® 350-conjugated Antibody

Recombinant Monoclonal Mouse IgG_1 Clone # 104918R

Catalog Number: FAB633RU

100 µg

DESCRIPTION	
Species Reactivity	Human
Specificity	Detects human TRAIL R4/TNFRSF10D in direct ELISAs.
Source	Recombinant Monoclonal Mouse IgG ₁ Clone # 104918R
Purification	Protein A or G purified from cell culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D Ala56-His211 Accession # Q9UBN6
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

AP				

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

lease Note. Optimal alliations should be determined by each aboratory for each application. School and available in the Technical Information Section on our website.				
	Recommended Concentration	Sample		
Flow Cytometry	0.25-1 μg/10 ⁶ cells	Human peripheral blood cells		

PREPARATION AND STORAGE

Sŀ	qqiı	ina '	The product is sl	nipped with polar	packs. U	lpon receipt	t. store it immediatel	v at the tem	perature recommended below.

Stability & Storage Protect from light. Do not freeze.

• 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Human TRAIL R4, also called decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a type I, TNF R family transmembrane protein, which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL R4 is designated as TNFRSF10D. TRAIL R4 is unique among the TRAIL receptors in that its cytoplasmic domain contains a truncated consensus death domain motif. Binding of TRAIL R4 does not result in an apoptotic signal. Overexpression of TRAIL R4 can protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-mediated apoptosis. The human soluble TRAIL R4/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.

References:

- 1. Griffith, T.S. et al. (1998) Curr. Opin. Immunol. 10:559
- 2. Pan, G. et al. (1998) FEBS lett 424:41.
- 3. Marsters, S.A. et al. (1997) Cur. Biol. 7:1003.
- 4. Degli-Esposti, M.A. et al. (1997) Immunity 7:813.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Rev. 12/15/2020 Page 1 of 1

